-
Mashup Score: 2FDA Approves Nirogacestat for Desmoid Tumors - 5 month(s) ago
This is the first drug approved to treat desmoid tumors.
Source: www.medscape.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4Pembrolizumab Wins Biliary Tract Cancer Indication - 6 month(s) ago
The new approval is the sixth gastrointestinal indication for the checkpoint inhibitor.
Source: www.medscape.comCategories: General Medicine News, General NewsTweet-
#FDAapproves pembrolizumab for locally advanced unresectable or metastatic biliary tract cancer in combination with gemcitabine and cisplatin. https://t.co/DH4B9Y2Mlm
-
-
Mashup Score: 5FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic Syndromes - 6 month(s) ago
The FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission.
Source: www.medscape.comCategories: General Medicine News, General NewsTweet-
#FDAapproves tablets of ivosidenib for adults with IDH-1 mutated relapsed or refractory myelodysplastic syndromes. https://t.co/Y2SuGqPYYb
-
-
Mashup Score: 2FDA Approves Subcutaneous Infliximab for IBD - 6 month(s) ago
The approval provides an alternative administration option for delivering the drug to patients with moderately to severely active ulcerative colitis or Crohn’s disease.
Source: www.medscape.comCategories: General Medicine News, General NewsTweet-
#FDAapproves infliximab-dyyb for maintenance therapy in adults with moderately to severely active ulcerative colitis and Crohn's disease after treatment with an intravenous infliximab product. https://t.co/Wppv5mBpj9 https://t.co/BL1LnU4tJK
-
-
Mashup Score: 0FDA Approves Nivolumab for Resected Stage IIB/C Melanoma - 6 month(s) ago
The new approval expands the melanoma indication for nivolumab to earlier-stage disease.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves nivolumab for the treatment of completely resected stage IIB/C melanoma for patients aged 12 years and older, expanding the #melanoma indication for the PD-1 inhibitor. https://t.co/aq4mm01bU4
-
-
Mashup Score: 0FDA Approves Intravenous Formulation of Secukinumab - 6 month(s) ago
This new route of administration is expected to become available during the fourth quarter of 2023.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves intravenous formulation of secukinumab https://t.co/adHDPt4Nu7 https://t.co/d6k5jnUIcO
-
-
Mashup Score: 1FDA Approves Novo Nordisk's Therapy for Rare Genetic Condition - 7 month(s) ago
Novo Nordisk said on Monday the FDA had approved its therapy to treat a rare genetic condition that affects the kidneys.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#FDAApproves Novo Nordisk's therapy for rare genetic condition #TwitteRx https://t.co/mjusRay6AT https://t.co/Kn6NEtdJEi
-
-
Mashup Score: 7FDA Approves New Indication for Avapritinib - 11 month(s) ago
Avapritinib (AYVAKIT) is now approved to treat adults with indolent systemic mastocytosis.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves avapritinib for the treatment of adults with indolent systemic mastocytosis. https://t.co/mFZARRe7SB
-
-
Mashup Score: 2FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease - 11 month(s) ago
The oral JAK inhibitor is for adults with moderately to severely active Crohn’s disease whose condition failed to respond adequately or who can’t tolerate one or more TNF inhibitors.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves upadacitinib, the first oral treatment for #Crohns disease. https://t.co/C2YSF48xzo
-
-
Mashup Score: 0FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease - 11 month(s) ago
The oral JAK inhibitor is for adults with moderately to severely active Crohn’s disease whose condition failed to respond adequately or who can’t tolerate one or more TNF inhibitors.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves JAK inhibitor upadacitinib for adults with moderately to severely active #Crohns disease whose condition failed to respond adequately or who can't tolerate one or more TNF inhibitors. https://t.co/wAnHWiQXJV
-
#FDAapproves nirogacestat to treat progressive, unresectable, recurrent, or refractory desmoid tumors in adults. https://t.co/nxTAiHdhrW https://t.co/2i4JINfVTs